NEU neuren pharmaceuticals limited

Ann: FDA approval for Phelan-McDermid IND and Phase 2 trial, page-11

  1. 512 Posts.
    lightbulb Created with Sketch. 1650
    I'm totally with you. But I don't think hat you say is quite true yet from a market perspective. A high likelihood of straight-to-bottom-line revenue of US$200m a year from 2023 doesn't match a US$400m MC today. Clearly the 'market' doesn't agree that Neuren is a different company yet. If 'they' did they'd be piling in and buying $20 million shares a day.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.96
Change
-0.140(1.07%)
Mkt cap ! $1.612B
Open High Low Value Volume
$13.20 $13.36 $12.82 $4.627M 354.8K

Buyers (Bids)

No. Vol. Price($)
1 7585 $12.96
 

Sellers (Offers)

Price($) Vol. No.
$13.03 3344 2
View Market Depth
Last trade - 16.10pm 16/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.